• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Longeveron Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8/13/25 4:10:50 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LGVN alert in real time by email
    false 0001721484 0001721484 2025-08-13 2025-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of

    the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): August 13, 2025

     

    Longeveron Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-40060   47-2174146
    (State or Other Jurisdiction
    of Incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    1951 NW 7th Avenue, Suite 520

    Miami, Florida 33136

    (Address of Principal Executive Offices)

     

    Registrant’s Telephone Number, Including Area Code: (305) 909-0840

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Class A Common Stock, $0.001 par value per share   LGVN   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

     

    Emerging Growth Company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    Item 2.02. Results of Operations and Financial Condition

     

    On August 13, 2025, Longeveron Inc. (the “Company”) issued a press release announcing its financial and operating results for the three and six months ended June 30, 2025 and certain other business updates and information. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

     

    The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for any purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    The exhibits listed in the following Exhibit Index are being furnished as part of this Current Report on Form 8-K.

     

    Exhibit No.   Description
    99.1   Press Release issued by the Company on August 13, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    1

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      LONGEVERON INC.
       
    Date: August 13, 2025 /s/ Wa’el Hashad
      Name:  Wa’el Hashad
      Title: Chief Executive Officer

     

     

    2

     

     

    Get the next $LGVN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LGVN

    DatePrice TargetRatingAnalyst
    12/6/2024$10.00Buy
    ROTH MKM
    1/5/2022$20.00Buy
    EF Hutton
    More analyst ratings

    $LGVN
    SEC Filings

    View All

    Longeveron Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Longeveron Inc. (0001721484) (Filer)

    10/1/25 4:29:44 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Longeveron Inc. (0001721484) (Filer)

    9/26/25 4:01:28 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - Longeveron Inc. (0001721484) (Filer)

    9/19/25 4:47:44 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel, Secretary Lehr Paul T covered exercise/tax liability with 4,944 shares, decreasing direct ownership by 1% to 351,129 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    10/3/25 6:00:10 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agafonova Nataliya covered exercise/tax liability with 11,883 shares, decreasing direct ownership by 5% to 226,814 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    10/3/25 6:00:13 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Powell James Nathaniel covered exercise/tax liability with 2,389 shares, decreasing direct ownership by 2% to 128,057 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    10/3/25 6:00:12 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

    MIAMI, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will participate in the 4th Annual ROTH Healthcare Opportunities Conference. Longeveron management will host one-on-one meetings with investors at the conference to be held October 9, 2025 in New York. About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company's lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell (M

    10/6/25 9:15:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors

    MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that George Paletta, Jr., MD, MBA, has been elected to the Longeveron Board of Directors. Dr. Paletta is a nationally and internationally recognized orthopedic surgeon and the head team doctor for the St. Louis Cardinals. Dr. Paletta is a developer of ambulatory surgical centers (ASCs), and has participated in the selling of two ASCs with deal values totaling almost $1 billion. "I am delighted to welcome George, and his tremendous experience as a physician, inv

    10/1/25 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

    Exploring potential partnerships and strategic opportunities for the Company's stem cell therapy program in Alzheimer's diseaseAlzheimer's disease development program with positive data in successful Phase 1 and Phase 2a clinical trialsClear regulatory pathway following positive Type B meeting with U.S. FDAFDA has granted laromestrocel both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer's disease MIAMI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today

    9/22/25 9:15:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Longeveron with a new price target

    ROTH MKM initiated coverage of Longeveron with a rating of Buy and set a new price target of $10.00

    12/6/24 7:54:21 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EF Hutton initiated coverage on Longeveron with a new price target

    EF Hutton initiated coverage of Longeveron with a rating of Buy and set a new price target of $20.00

    1/5/22 10:22:40 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baluch Khoso bought 11,766 shares, increasing direct ownership by 29% to 52,516 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    8/13/25 6:00:07 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Locklear Lisa bought 11,766 shares, increasing direct ownership by 5% to 250,964 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    8/13/25 6:00:08 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hare Joshua bought $350,000 worth of shares (148,936 units at $2.35), increasing direct ownership by 31% to 633,280 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    4/12/24 7:00:29 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Leadership Updates

    Live Leadership Updates

    View All

    George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors

    MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that George Paletta, Jr., MD, MBA, has been elected to the Longeveron Board of Directors. Dr. Paletta is a nationally and internationally recognized orthopedic surgeon and the head team doctor for the St. Louis Cardinals. Dr. Paletta is a developer of ambulatory surgical centers (ASCs), and has participated in the selling of two ASCs with deal values totaling almost $1 billion. "I am delighted to welcome George, and his tremendous experience as a physician, inv

    10/1/25 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® Appoints Than Powell as Chief Business Officer

    Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In this role, he will lead the Company's overall business strategy, Alzheimer's disease program partnering efforts, and international strategy for the hypoplastic left heart syndrome (HLHS) program. "We are delighted to have Than join Longeveron at this transformational time in the Company's

    6/26/25 9:05:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

    MIAMI, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Devin Blass as Chief Technology Officer (CTO) and Senior Vice President of Chemistry, Manufacturing, and Controls (CMC), effective December 2, 2024. In this role, he will lead the Company's technological and manufacturing strategies. "We are delighted to have Devin join Longeveron at this transformational time in the Company's evolution," said Wa'el Hashad, Chief Executive Officer at Longeveron. "This appointment reinforces Longevero

    11/11/24 9:05:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Longeveron Inc.

    SC 13G/A - Longeveron Inc. (0001721484) (Subject)

    11/14/24 4:20:18 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Longeveron Inc.

    SC 13G - Longeveron Inc. (0001721484) (Subject)

    7/26/24 4:18:08 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Longeveron Inc.

    SC 13G - Longeveron Inc. (0001721484) (Subject)

    4/17/24 4:03:33 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Financials

    Live finance-specific insights

    View All

    Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

    MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report second quarter 2025 financial results and provide a business update on Wednesday, August 13, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details:  Conference Call Number:1.877.407.0789Conference ID:13754295  Call meTM Feature:Click HereWebcast:Click Here   An archived replay of the webcast will be available on t

    8/5/25 9:15:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

    Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to complete enrollment in the second quarter of 2025Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II is successfulResults from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer's disease were published in Nature MedicinePositive FDA meeting regarding development pathway for laromestrocel in mild Alzheimer's disease; single, pivotal Phase 2/3 adaptive design clinica

    5/8/25 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

    MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report first quarter 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details:      Conference Call Number:    1.877.407.0789 Conference ID:    13752361     Call meTM Feature:  Click HereWebcast:  Click Here     An archived replay of the webcast will be available o

    5/2/25 8:30:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care